Anti-müllerian hormone level in patients with polycystic ovary syndrome
Author(s) -
SalarMohammed Saadullah,
DhiaMustafa Sulaiman
Publication year - 2018
Publication title -
medical journal of babylon
Language(s) - English
Resource type - Journals
eISSN - 2312-6760
pISSN - 1812-156X
DOI - 10.4103/mjbl.mjbl_98_18
Subject(s) - anti müllerian hormone , polycystic ovary , medicine , anovulation , hyperandrogenism , antral follicle , hormone , gynecology , ovarian reserve , case control study , endocrinology , infertility , pregnancy , insulin resistance , insulin , biology , genetics
Background: Polycystic ovary syndrome (PCOS) is one of the common causes of chronic anovulation and hyperandrogenism in women between the age of 13 and 45 years old. PCOS is characterized by an increased number of follicles at all growing stages particularly in the preantral and small antral follicles, those who primarily produce Anti-Müllerian hormone (AMH). Objective: The aim of the study is to measure the AMH levels in serum of the women with PCOS. Materials and Methods: The study included 90 women (50 cases with PCOS and 40 control cases healthy women). PCOS patients were diagnosed according to the Rotterdam definition; serum AMH was measured using the ultrasensitive AMH enzyme-linked immunosorbent assay. Results: Mean serum of AMH in PCOS patients was 11.52 ng/ml and for the control group was 3.36 ng/ml and was statistically significant with the P < 0.0001. Conclusions: AMH is elevated in PCOS patients, which can be used in the future as a marker for the diagnosis of PCOS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom